AsedaSciences
AsedaSciences operates the 3RnD cloud platform, combining AI-driven machine learning with proprietary high-content cellular, zebrafish, and chromatography screening to predict compound toxicity for pharmaceutical, biotechnology, agricultural chemical, cosmetics, and academic drug discovery customers worldwide.
- Company typePrivate
- Founded2012
- HeadquartersWest Lafayette, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What AsedaSciences does
AsedaSciences operates the 3RnD platform, a cloud-based, AI-driven ecosystem that combines machine learning with proprietary high-content cellular screening to predict human toxicity risk and support the design of safer chemical and pharmaceutical compounds. The platform is built around the generation of standardized biological fingerprints using SYSTEMETRIC flow-cytometry-based multiparametric screens (12 cellular stress parameters across 10 concentrations), with proprietary ML algorithms comparing new compound fingerprints against a library of 3,000+ historical fingerprints to generate a Cell Health Index risk score. Native integration with 3RnD also covers complementary screening modalities including ZBEScreen zebrafish screening (16 organ and behavioral endpoints via partnership with Tanguay Lab), Biomimetic Chromatography (Valko Screen, 6 endpoints developed with Dr. Klara Valko), compound QC, and a Kinome profiling module; visualization layers include Compound Universe, Zebrafish Universe, and Kinome Universe, with add-on tools such as the SciScore NLP engine (scoring research rigor across 2.2M+ publications) and GOSTAR compound reports from Excelra.
The company monetizes through four streams: SaaS subscriptions to the 3RnD platform on tiered monthly plans ranging from a free entry tier through a $299/month commercial tier; pay-as-you-go contract screening services priced $180-$2,000 per test depending on assay complexity; enterprise software licensing for SciScore and specialized tools; and premium access to proprietary datasets including the 3,000+ compound biological fingerprint database. Go-to-market is hybrid: a product-led freemium motion at the individual researcher level, direct enterprise field sales targeting pharma and biotech for full-service screening contracts, and regional channel partners (e.g., Chayon Laboratories for South Korea). Customer segments span pharmaceutical and biotechnology companies (primary), agricultural chemicals, industrial chemicals, cosmetics, food safety, and academic drug discovery groups across 186 countries.
The company is incorporated as AsedaSciences AG in Schindellegi, Switzerland (global headquarters) and AsedaSciences Inc. in West Lafayette, Indiana (US operations and laboratory facilities). Operative leadership is led by co-founder and CEO Brad Calvin, who previously held executive roles at Abbott, Digene, Beckman Coulter, and MaxCyte. The company reports 1-10 employees per firmographic data (though operations include 18+ active integration and channel partnerships), privately held, with no disclosed funding rounds, revenue, or institutional ownership in the available source material.
AsedaSciences firmographics
Firmographics- Name
- AsedaSciences
- Legal name
- AsedaSciences AG
- Website
- https://asedasciences.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- AsedaSciences operates the 3RnD cloud platform, combining AI-driven machine learning with proprietary high-content cellular, zebrafish, and chromatography screening to predict compound toxicity for pharmaceutical, biotechnology, agricultural chemical, cosmetics, and academic drug discovery customers worldwide.
- Ownership category
- akta.pro rank
AsedaSciences industry classification
Industry- Product category
- Computational Toxicology Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Testing Laboratories and Services (54138)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ)
- akta.pro secondary industries
- Method Development & Validation (ICH/USP) (HLAGADAB), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Pesticide Residue & Agrochemical Screening Services (Soil/Plant/Water) (AFACAKAF)
Keywords
Where AsedaSciences is headquartered
LocationHeadquarters
- HQ city
- West Lafayette
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
AsedaSciences business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- SaaS Platform Subscriptions: Monthly and annual subscription tiers for the 3RnD platform providing tiered access to compound screening tools, data visualization, and AI-powered analytics. Revenue recurs on a subscription basis with annual discounts available.
- Contract Screening Services: Per-test and project-based screening services using zebrafish models, biomimetic chromatography, and cell-based assays. Revenue generated through individual test fees ranging from $180 to $2,000 depending on assay complexity.
- Software Licensing: Enterprise licensing of SciScore and specialized screening tools for pharmaceutical and biotech clients requiring dedicated deployments or on-premise installations.
- Data and Analytics: Access to proprietary datasets including GOSTAR database integration and historical compound screening data, provided as premium add-on services to platform subscribers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free tier for individual researchers to explore basic 3RnD platform functionality |
| Subscription | Monthly | Starter plan for small research teams needing enhanced capabilities |
| Subscription | Monthly | Academic-focused plan with research-specific tools and reduced pricing |
| Subscription | Monthly | Full commercial access for pharmaceutical and biotech organizations |
| Unit Pricing | Pay-as-you-go | SciScore credit packages for research methodology evaluation |
| Unit Pricing | Pay-as-you-go | In vivo zebrafish screening for developmental and acute toxicity assessment |
| Unit Pricing | Pay-as-you-go | Blood-brain barrier permeability and tissue distribution prediction |
| Unit Pricing | Pay-as-you-go | Quality control and purity verification for compound libraries |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
AsedaSciences product offering
Product offeringCore offering
AsedaSciences provides multi-parametric phenotypic screening services and a cloud-based AI-driven platform (3RnD) for compound safety assessment. The company combines proprietary high-content cellular screening (SYSTEMETRIC), zebrafish embryo screening (ZBEScreen), and biomimetic chromatography with machine learning algorithms to generate biological fingerprints that predict human and environmental toxicity risk without animal testing. Services and software target pharmaceutical, biotech, agrochemical, cosmetics, and academic drug discovery organizations.
Product overview
AsedaSciences offers a cloud-based AI-driven platform ecosystem centered on the 3RnD platform, which integrates chemistry, biology, and toxicology data through ML-powered visualization tools. The core 3RnD platform is supported by proprietary screening services including SYSTEMETRIC Cell Health Screen (measuring 12 cellular stress endpoints), ZBEScreen zebrafish screening (16 endpoints), and Biomimetic Chromatography (6 endpoints). The platform features specialized visualization modules including Compound Universe, Zebrafish Universe, and Kinome Universe for comparative compound analysis. Add-on services include SciScore for publication rigor assessment and GOSTAR compound reports for SAR data. The platform is available through tiered subscription plans (Basic/Starter/Academic+/Commercial) and integrates third-party screening and data services from partners including AssayQuant, CellPort Software, and Chemspace.
Differentiator
Problem solved
Functional benefit
Brands
- 3RnD: Cloud-based AI-driven platform that enables scientists to visualize and explore the relationship between chemical structure and biological effects to design safer compounds. Integrates chemistry, biology, and toxicology data with machine learning and elegant visualization tools.
- SYSTEMETRIC
- ZBEScreen
- Compound Universe
- SciScore
- NAM Central
Products and services
- 3RnD Platform Cloud-based AI-driven platform integrating chemistry, biology, and toxicology data visualization to help scientists predict toxicity risk and design safer compounds. Available to pharmaceutical, biotech, agrochemical, cosmetics, food safety, and academic research organizations through tiered subscription plans.
- SYSTEMETRIC Cell Health Screen Proprietary high-content flow cytometry-based phenotypic screening service measuring 12 parameters of cellular stress across 10 concentrations to generate biological fingerprints for ML-based acute toxicity risk prediction. Used by pharmaceutical and chemical companies for early safety assessment.
- ZBEScreen Zebrafish Screening Service Zebrafish embryo screening service measuring 16 organ and behavioral endpoints for developmental and acute neurotoxicity assessment, offered in collaboration with Tanguay Lab at $629-$1,999 per compound. Used by pharmaceutical and chemical companies for in vivo toxicity screening.
- Biomimetic Chromatography Screening (Valko Screen) HPLC-based analytical screening service assessing drug properties including lipophilicity, human protein binding, and phospholipid binding as indicators of in vivo distribution and toxicity risk, offered at $390-$450 per compound. Developed in collaboration with Dr. Klara Valko.
- Compound QC Quality control screening service measuring compound stability and solubility using HPLC methods at $180-$200 per compound. Supports compound library curation and integrity verification for pharmaceutical and biotech clients.
- SciScore NLP-based tool that automatically assesses and scores scientific rigor of materials and methods sections in publications to improve research reproducibility. Sold via credit packages ($39.99 academic / $49.99 commercial for 3 credits) to researchers and institutions.
- GOSTAR Compound Reports Downloadable compound annotation reports integrating Excelra's GOSTAR database (10M+ chemical structures) into the 3RnD platform, providing SAR insights and historical compound data for drug discovery researchers.
Quantifiable outcome
- 18,000+ research teams actively using the platform across 186 countries
- +1 more outcomes
Companies that use AsedaSciences
Customer profileSegments7 records
Ideal customer profiles4 records
AsedaSciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability7 records
Feature6 records
AsedaSciences partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core, major, minor and regional.
- Tanguay LabcoreResearch collaboration with Tanguay Lab for zebrafish screening methodology development. Provides expertise in developmental toxicity assessment and assay optimization for the Zebrafish Universe platform.
- EuroscreenFastmajorGPCR screening partnership providing access to comprehensive G-protein coupled receptor binding data for off-target toxicity assessment during compound profiling.
- Dr. Klara ValkocoreScientific collaboration with Dr. Klara Valko for development and commercialization of Biomimetic Chromatography technology (Valko Screen) for blood-brain barrier permeability and tissue distribution prediction.
- CytionmajorCell line partnership providing authenticated cell lines for screening validation. Ensures reproducibility and quality of cell-based assay results integrated into the platform's toxicity prediction workflows.
- Excelra (GOSTAR)coreGOSTAR database integration providing access to 28 million+ curated small molecule records with pharmacological and toxicity data. Enhances platform's training datasets and enables benchmarking against historical compound data.
- Supreme OptimizationminorDigital marketing partnership for demand generation and lead acquisition activities targeting pharmaceutical and biotech decision-makers in key markets.
- Chayon LaboratoriesregionalRegional reseller partnership for South Korea market. Chayon Laboratories serves as authorized distributor providing local sales, customer support, and implementation services for Korean customers.
- CellPort SoftwaremajorIntegration of cell culture management capabilities enabling users to track and manage cell-based assay data within the 3RnD platform. Provides seamless data transfer for improved workflow efficiency.
- AssayQuantcoreIntegration of KinSight Kinome profiling technology enabling comprehensive kinase activity screening within the platform. Provides quantitativekinase binding data for off-target toxicity prediction.
- ChemspacecoreIntegration providing access to 13 billion+ virtual compounds for computational screening. Enables users to explore extensive chemical space and perform virtual screening against the company's proprietary toxicity models.
- EuretoscoreAI-driven disease research integration providing transcriptomic and proteomic data to enhance compound mechanism-of-action predictions within the 3RnD platform. Enables correlation of gene expression changes with toxicity endpoints.
- SimplicismajorPartnership for compound screening and management services enabling seamless data flow between Simplicis screening workflows and 3RnD platform analysis tools for streamlined drug discovery processes.
- Frontier ScientificmajorCompound management services partnership providing sample handling, storage, and logistics for client compounds. Ensures integrity and traceability of materials throughout screening workflows.
- Cayman ChemicalmajorCompound library partnership providing reference compounds and screening standards for assay validation. Enables access to curated chemical libraries for quality control and method development.
- HesperoscoreIntegration partnership enabling Human-on-a-Chip organ system data within the 3RnD platform. Allows users to access multi-organchip toxicity data alongside traditional screening results for comprehensive safety assessment.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
AsedaSciences competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights7 records
Customer concentration
AsedaSciences social profiles
Digital presenceAsedaSciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
AsedaSciences leadership team
Management profileNumber of profiles
Profiles1 record
AsedaSciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AsedaSciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AsedaSciences
What does AsedaSciences do?
AsedaSciences provides multi-parametric phenotypic screening services and a cloud-based AI-driven platform (3RnD) for compound safety assessment. The company combines proprietary high-content cellular screening (SYSTEMETRIC), zebrafish embryo screening (ZBEScreen), and biomimetic chromatography with machine learning algorithms to generate biological fingerprints that predict human and environmental toxicity risk without animal testing. Services and software target pharmaceutical, biotech, agrochemical, cosmetics, and academic drug discovery organizations.
Is AsedaSciences a public or private company?
AsedaSciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was AsedaSciences founded?
AsedaSciences was founded in 2012. It employs 1 to 10 people.
Where is AsedaSciences based?
AsedaSciences is headquartered in West Lafayette, United States, in the North America region.
How does AsedaSciences make money?
Four revenue lines are on record. SaaS Platform Subscriptions are the primary driver. The others are contract Screening Services, software Licensing and data and Analytics.
Does AsedaSciences have an API?
No public API is recorded for AsedaSciences.
What industry is AsedaSciences in?
AsedaSciences's product category is Computational Toxicology Software. Its primary akta.pro industry code is HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip), with a secondary code of HLAGADAB, Method Development & Validation (ICH/USP). Its NAICS code is 541714 and its SIC code is 8731.